Gedeon Richter Nyrt, Hungary’s biggest drug maker, has signed a licence agreement with Japan’s Mochida Pharmaceutical, providing the biosimilar manufacturer with a good foothold in the lucrative Japanese pharmaceuticals market.

The deal gives Mochida exclusive rights to develop, market and distribute the Richter portfolio in Japan.

Mochida will contribute to the development costs of Richter’s biosimilar products and will make payments related to the fulfilment of certain regulatory criteria, according to a Richter statement.

Richter has forged strong international links this year, first with the acquisition of PregLem, a privately owned Swiss biopharmaceutical company, then with a deal for the oral contraceptive portfolio of Grunenthal, a family owned, research-based company based in Germany, for €236.5m.